


Statement of Unaudited Results for the Quarter and Half year ended September 30, 2016

(Rs. in Lakhs except earnings per share)

	Particulars	Quarter ended	Quarter ended	Quarter ended	Six Months ended	Six Months ended
		September 30, 2016	June 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
<b>1</b>	<b>Income from Operations</b>					
	(a) Sales (Inclusive of Excise Duty)	721,14	731,33	640,26	1452,47	1271,00
	(b) Other Operating Income	8,29	6,79	8,72	15,08	15,24
	<b>Total Income from Operations</b>	<b>729,43</b>	<b>738,12</b>	<b>648,98</b>	<b>1467,55</b>	<b>1286,24</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of Materials Consumed	95,97	71,85	70,28	167,82	151,48
	(b) Purchase of Stock-in-Trade	432,72	365,92	301,18	798,64	514,15
	(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(98,99)	(18,37)	(5,64)	(117,36)	60,26
	(d) Employee Benefits Expense	86,85	85,81	86,84	172,66	172,67
	(e) Depreciation and Amortization Expense	4,08	4,16	3,42	8,24	6,78
	(f) Other Expenses	106,89	127,51	109,78	234,40	206,63
	<b>Total Expenses</b>	<b>627,52</b>	<b>636,88</b>	<b>565,86</b>	<b>1264,40</b>	<b>1111,97</b>
<b>3</b>	<b>Profit from operations before Other Income, Finance Costs (1-2)</b>	<b>101,91</b>	<b>101,24</b>	<b>83,12</b>	<b>203,15</b>	<b>174,27</b>
<b>4</b>	<b>Other Income</b>	<b>14,35</b>	<b>13,94</b>	<b>13,10</b>	<b>28,29</b>	<b>25,62</b>
<b>5</b>	<b>Profit before Finance Costs (3+4)</b>	<b>116,26</b>	<b>115,18</b>	<b>96,22</b>	<b>231,44</b>	<b>199,89</b>
<b>6</b>	<b>Finance Costs</b>	<b>1</b>	<b>2</b>	<b>41</b>	<b>3</b>	<b>44</b>
<b>7</b>	<b>Profit before tax (5-6)</b>	<b>116,25</b>	<b>115,16</b>	<b>95,81</b>	<b>231,41</b>	<b>199,45</b>
<b>8</b>	<b>Tax Expense</b>	<b>41,23</b>	<b>41,15</b>	<b>34,65</b>	<b>82,38</b>	<b>70,98</b>
<b>9</b>	<b>Net Profit for the Period (7-8)</b>	<b>75,02</b>	<b>74,01</b>	<b>61,16</b>	<b>149,03</b>	<b>128,47</b>
<b>10</b>	<b>Other Comprehensive Income (after Tax)</b>					
	- Items that will not be classified to Profit or Loss	-	-	(25)	-	(50)
	- Items that will be classified to Profit or Loss	-	-	-	-	-
	Total Other Comprehensive Income (after Tax)	-	-	(25)	-	(50)
<b>11</b>	<b>Total Comprehensive Income for the period (9+10)</b>	<b>75,02</b>	<b>74,01</b>	<b>60,91</b>	<b>149,03</b>	<b>127,97</b>
<b>12</b>	<b>Paid-up Equity Share Capital (Face Value Rs.10 per Equity Share)</b>	<b>21,25</b>	<b>21,25</b>	<b>21,25</b>	<b>21,25</b>	<b>21,25</b>
<b>13</b>	<b>Earnings Per Share (EPS) (of Rs. 10/- each) (not annualised):</b>					
	a. Basic	35.30	34.83	28.66	70.13	60.22
	b. Diluted	35.30	34.83	28.66	70.13	60.22

SIGNED FOR IDENTIFICATION  
BY  
  
S R B C & CO LLP  
MUMBAI

Statement of Assets and Liabilities

(Rs. in Lakhs)	
As at	
September 30, 2016	
Unaudited	
<b>ASSETS</b>	
<b>Non-Current Assets</b>	
Property, plant and equipment	103,25
Capital work-in-progress	5,50
Other Intangible assets	1,99
Intangible assets under development	1,54
Financial Assets	
Loans	23,84
Others	3,04
Deferred Tax Assets (Net)	11,21
Other Non-Current Assets	20,40
<b>Total Non-Current Assets</b>	<b>170,77</b>
<b>Current Assets</b>	
Inventories	476,62
Financial Assets	
Trade Receivables	177,30
Cash and Cash equivalents	216,09
Bank Balances other than above	656,06
Loans	20,51
Other Financial Assets	12,43
Current Tax Assets (Net)	13,01
Other Current Assets	50,00
<b>Total Current Assets</b>	<b>1622,02</b>
<b>TOTAL ASSETS</b>	<b>1792,79</b>
<b>EQUITY AND LIABILITIES</b>	
<b>Equity</b>	
Share Capital	21,25
Other Equity	1235,27
<b>Total Equity</b>	<b>1256,52</b>
<b>Non-Current Liabilities</b>	
Provisions	46,75
<b>Total Non-Current Liabilities</b>	<b>46,75</b>
<b>Current Liabilities</b>	
Financial Liabilities	
Trade Payables	328,24
Other Financial Liabilities	35,45
Other current liabilities	39,22
Provisions	65,57
Current Tax Liabilities (Net)	21,04
<b>Total Current Liabilities</b>	<b>489,52</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1792,79</b>

Notes :

- 1 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2016, the Company has for the first time adopted Ind AS with a transition date of April 1, 2015. The impact of transition has been accounted for in opening reserves and the comparative period results have been restated accordingly. These however have not been subjected to limited review or audit. The management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the Company's affairs. The opening balance sheet as of April 1, 2015 and the results for the subsequent periods would get finalised along with the annual financial statements for the year ending March 31, 2017.
- 2 The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on November 28, 2016.
- 3 The Company operates in single reportable business segment i.e. "Pharmaceuticals" and single reportable geographical segment i.e. "Within India".
- 4 The format for un-audited quarterly and half yearly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.

**SIGNED FOR IDENTIFICATION**  
**BY**  
  
**S R B C & CO LLP**  
**MUMBAI**

5 The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with IND AS is given below :

	(Rs. in Lakhs)	
	Quarter ended September 30, 2015	Six Months ended September 30, 2015
<b>Net Profit under Previous GAAP</b>	<b>61,70</b>	<b>130,26</b>
<b>Add/(Less) : Adjustments of</b>		
Cost of employee share based payments	(1,73)	(3,44)
Actuarial loss on employee defined benefit funds recognized in Other Comprehensive Income	38	76
Physicians samples written off	1,65	1,76
Others	1	1
Deferred Tax impact on IND AS adjustments	(85)	(88)
<b>Net Profit for the period under IND AS</b>	<b>61,16</b>	<b>128,47</b>
Other Comprehensive Income (after Tax)	(25)	(50)
<b>Total Comprehensive Income for the period</b>	<b>60,91</b>	<b>127,97</b>

6 Figures for the previous period have been regrouped/reclassified wherever considered necessary.

Place : Mumbai  
Date : November 28, 2016

*[Handwritten signature]*



For and on behalf of the Board of Directors of  
Abbott India Limited

*[Handwritten signature]*  
Mr Ambati Venu  
Managing Director  
DIN : 07614849